• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only


      November: Episode 5     Watch time: 20 min

      Are all IL-23s the same?

      The fifth episode explores how differences within the IL-23 inhibitor class may affect efficacy, safety and dosing outcomes for patients with moderate to severe psoriasis, with a focus on IL-23p19 inhibitors, including SKYRIZI® (risankizumab).

      Podcast Series Host

      Dr Laura Savage

      Consultant Dermatologist at Leeds Centre for Dermatology, Chapel Allerton Hospital (Leeds Teaching Hospitals NHS Trust) and an Honorary Senior Lecturer at University of Leeds

      Podcast Guest Speakers

      Dr Shirin Zaheri

      Imperial Healthcare NHS Trust and Imperial College London


      Professor Kave Shams

      University of Leeds and Leeds Centre for Dermatology



      JULY: Episode 1

      Clinical trial spotlight - risankizumab and secukinumab head-to-head in plaque psoriasis

      AUGUST: Episode 2

      Psoriasis in the time of COVID-19: an era of virtual clinics?             

      SEPTEMBER: Episode 3

      Psoriasis in practice: BAD guideline updates                               

      OCTOBER: Episode 4

      BAD 2020: virtual congress highlights

      NOVEMBER: Episode 5

      Are all IL-23s the same?                    

      DECEMBER: Episode 6

      EADV 2020: congress highlights       


      1. SKYRIZI (risankizumab) Summary of Product Characteristics.

      UK-RISN-210517 Date of Preparation: October 2021